RecruitingNCT06307184

Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer

Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer: an Ambispective Cohort Study


Sponsor

Instituto Valenciano de Infertilidade de Lisboa

Enrollment

530 participants

Start Date

Feb 23, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This study will assess the convenience of the natural proliferative phase frozen embryo transfer (NPP-FET) in terms of number of number of appointments needed before cycle scheduling.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 49 Years

Inclusion Criteria7

  • Endometrial thickness ≥ 7 mm on the day of starting progesterone-based luteal phase support (LPS)
  • Serum progesterone levels \<1.5 ng/ml on the day of starting progesterone-based LPS
  • LPS with micronized progesterone 400mg b.i.d.
  • Regular cycles (\>24 days, ≤ 38 days)
  • IVF/ICSI with donated oocytes
  • Single blastocyst stage embryo transfer
  • First or second embryo transfer from the same cohort

Exclusion Criteria5

  • Use of exogenous ovarian stimulation during FET
  • Untreated hydrosalpinx, polyp, submucous myomas or severe adenomyosis
  • Recurrent pregnancy loss (≥ 3 previous pregnancy losses)
  • Recurrent implantation failure with embryos from oocyte donation (≥ 3 previous failed embryo transfers)
  • Personalized initiation of exogenous progesterone according to a previous endometrial receptivity assay test

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURENatural proliferative phase frozen embryo transfer

When endometrial thickness is above 7 mm, vaginal micronized progesterone will be administered 400mg 12/12h when the dominant follicle is at least 13 mm, serum estradiol (E2) levels are \>80 pg/ml, and serum progesterone levels are \<1.5ng/ml. Embryo transfer will be performed on the fifth day of progesterone.


Locations(1)

Instituto Valenciano de Infertilidade

Lisbon, Portugal

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06307184


Related Trials